Skip Navigation

Faculty Directory

Dagna Constenla, PhD

  • Associate (Research) Professor
  • Director, Economics and Finance, IVAC
  • Associate Scientist

Departmental Affiliations

Center & Institute Affiliations

Contact Information

E8-132, 615 N. Wolfe St
Baltimore, Maryland 21205

(410) 955-1074
(443) 287-6714

Personal website:


PhD, 2006


Dr. Dagna Constenla has over 20 years of experience in the economic evaluation of health interventions, 15 of these have centered on the evaluation of pediatric vaccines. Her research on the measurement of the value of vaccines has been wide-ranging. She was one of the first in Latin America to develop a conceptual framework that allowed the differing incremental cost-effectiveness of vaccination between countries to be understood in context and to point the way towards a general approach that might be used by the public health community to plan future vaccination programs in the region.

Dr. Constenla’s work has focused mainly on gaining a better understanding of the economics of pediatric and adult vaccination in countries of emerging economies. Her methodological interest center mainly on the need to use standardized methods for economic analyses of vaccination programs, the suitability of study endpoints, the generalisability and representativeness of data, and how variable data can best be applied to local situations. Dr. Constenla recently shifted her attention to develop innovative financial tools to value dengue, malaria and meningococcal vaccination programs in countries that need it most.

Before joining Johns Hopkins University, Dr. Constenla worked many years as consultant for several national and international organizations. In this role, Dr. Constenla led health economic programs to evaluate rotavirus, pneumococcal, meningococcal, HPV, malaria and West Nile vaccination in several countries in Latin America, Sub-Sahara Africa, Europe and North America. Major achievements of these programs include the conduct of various training workshops with experts in the region, and production of local and regional papers.

Dr. Constenla has organized training and taught courses in health economics, health policy and health promotion and health services research to public health professionals in academic institutions of the UK and Latin America. She continuously supports academic activities in the following courses: public health management, social policy analysis, outcomes research. Dr. Constenla has contributed intellectually to a number of international scientific committees. 

Honors and Awards

Pre-Doctoral Fellow, Bill & Melinda Gates Foundation Award

Pre-Doctoral Fellow, Pan-American Health Organization Grant Award

The Dean’s Alumni Advisory Council Scholarship

McNair Scientific Research Scholar

Dean Lesher Scholarship Award

Betty Baldwin Scholarship Award

Kennedy-King Scholarship Award

Teacher’s Association Award

Golden Key National Honor Society Fellow

  • Economics of vaccines, finance of vaccines, vaccine-preventable diseases, vaccination programs,evidence-based decision-making, developing countries
  • costing methodology, generalizability and representativeness of data, pneumococcal pneumonia, rotavirus gastroenteritis, malaria, meningitis, cervical cancer, West Nile Virus, dengue

Selected peer-reviewed publications

  • Constenla D. Evaluating the economic impact of a pneumococcal conjugate vaccination program in Ecuador, Honduras and Paraguay. Pan Am J Public Health 2015 (in press).         

    Constenla D, Armien B, Arredondo J, Carabali M, Carrasquilla G, Castro R, Durand L, Durán-Arenas L, García ME, Gallegos V, Gontes M, López JG, McFarlane C, Montoya R, Sartori AMC, Siqueira JB, Martelli C . Costing dengue fever cases and outbreaks: Recommendations from a costing dengue working group in the Americas. Value in Health Regional Issues. 2015. DOI 10.1016/j.vhri.2015.06.001

    Constenla D, Garcia C, Lefcourt N, on behalf of the Dengue Costing Working Group. Assessing the economics of dengue: results from a systematic review of the literature. PharmacoEconomics J. 2015. DOI 10.1007/s40273-015-0294-7.

    Constenla D. Assessing economic benefits of vaccines based on the health investment life course framework: A review of a broader approach to evaluate malaria vaccination. Vaccine J 2015;33(13):1527-40.

    Lee BY, Moss WJ, Privor-Dumm, L, Constenla DO, Knoll MD, O’Brien KL. Is the world ready for an Ebola vaccine? The Lancet. 2015;385(9964):203-4.

    Thiry G, Hombach J, Constenla D, Carvalho A, Durbin A. New chapter unfolding in the fight against dengue with an unwritten ending. Trans R Soc Trop Med Hyg 2014; 108: 597–598

    Herzer K, Niessen L, Constenla D, Ward WJ, Pronovost PJ. Cost-effectiveness of a quality improvement programme to reduce central line associated bloodstream infections in intensive care units in the United States. BMJ Open 2014;4:e006065. doi:10.1136/bmjopen-2014-006065

    Pinzón-Redondo H, Coronell-Rodriguez W, Díaz-Martinez I, Guzmán-Corena A, Constenla D, Alvis-Guzmán N. Estimating the costs associated with a community outbreak of meningococcal disease in a Colombian Caribbean City. J Health Pop Nutr 2014;32(3):539-548. 

    Bärnighausen T, Berkley S, Bhutta ZA, Bishai D, Black MM, Bloom DE, Constenla D, Driessen J, Edmunds J, Evans D, Griffiths U, Hansen P, Hashmani FN, Hutubessy R, Jamison DT, Jha P, Jit M, Johnson H, Laxminarayan R, Lee BY, Mhatre S, Mills A, Nörsrrom A, Ozawa S, Prosser L, Silver K, Stabell Benn C, Standaert B, Walker D. Reassessing the value of vaccines. The Lancet Global Health 2014;2(5):e251-e252.

    Patel HD, Roberts ET, Constenla DO. Cost-Effectiveness of a new Rotavirus Vaccination Program in Pakistan: a Decision Tree Model. Vaccine 2013; 31(51):6072-8.

    Constenla D, Lefcourt N, Garcia C. Expert consensus building in developing guidelines: Lessons learned form a dengue economics workshop in the Americas. Pan Am J Public Health 2013;34(3):198-203.

    Sicuri E, Vieta A, Lindner L, Constenla D, Sauboin C. The economic costs of malaria in children in three Sub-Saharan countries: Ghana, Tanzania and Kenya. Malaria J 2013, 12:307.

    Constenla D, Sinha A, Valencia JE, Gomez E, de la Hoz F, Valenzuela MT, de Quadros CA. Identifying unit costs for use in regional economic evaluation: An example of an economic analysis of childhood pneumococcal conjugate vaccine in Latin America and the Caribbean. Pan Am J Public Health 2009;26(5):458-68.

    Vespa G, Constenla DO, Pepe C, Safadi MA, de Moraes JS, Herreiras de Campos CA, Araujo DV, de Andrade ALSS. Estimating the Cost-effectiveness of Pneumococcal Conjugate Vaccination in Brazil. Pan Am J Public Health 2009;26(6):518-28.

    Constenla D, Velázquez FR, Rheingans RD, Antil L, Cervantes Y. Economic impact of a rotavirus vaccination program in Mexico. Pan Am J Public Health. 2009;25(6):481-490.

    Valenzuela MT, O’Loughlin R, de la Hoz FP, Gomez E, Constenla D, Sinha A, Valencia JE, Flanner B, de Quadros C for the Technical Advisory Group. The burden of pneumococcal disease among Latin America and the Caribbean children: a review of the evidence. Pan Am J Public Health 2009:25(3):270-279.

    Constenla D, Linhares A, Rheingans RD, Antil L, Waldman EA, da Silva LJ. Economic impact of a rotavirus vaccine in Brazil. Journal Health Popul Nutr 2008;26:388-396.

    Sinha A, Constenla D, Valencia JE, O’Loughlin R, Gomez E, de la Hoz F, Valenzuela MT, de Quadros CA. The cost-effectiveness of pneumococcal conjugate vaccine in Latin American and the Caribbean: A regional analysis. Pan Am J Public Health 2008;24(5):304-13.

    Constenla D. Economic impact of pneumococcal conjugate vaccination in Brazil, Chile, and Uruguay. Rev Panam Salud Publica. 2008;24(2):101–12.

    Goldie SJ, Diaz M, Constenla D, Alvis N, Andrus JK, Kim SY. Mathematical models of cervical cancer prevention in Latin America and the Caribbean. Vaccine. 2008;26(S11):L59-72.

    Constenla D, Ortega E, Rheingans R, Antil L, Saez-Llorens X. Impacto Económico de la Vacuna Antirrotavírica en Panamá. Anales de Pediatría 2008;68(2):128-135.

    Constenla D. Evaluating the costs of pneumococcal disease in selected Latin American countries. Pan Am J Public Health 2007:22(4);268-278.

    Rheingans RD, Constenla D, Antil L, Innis B, Breuer T. Cost-Effectiveness of vaccination for rotavirus gastroenteritis in Latin America. Pan Am J Public Health 2007;21(4):205-216.

    Rheingans RD, Constenla D, Antil L, Innis B, Breuer T. Economic and health burden of rotavirus gastroenteritis in Latin America. Pan Am J Public Health 2007;21(4):192-204.

    Constenla D, O’Ryan M, Rheingans RD, Antil L, Navarrete M. Evaluación de costo-efectividad de la vacuna anti-rotavirus en Chile. Rev Méd Chile 2006;134(7):679-688.

    Constenla D, Pérez-Schael I, Rheingans R, Antil L, Salas H, Yarzábal JP. Evaluación del impacto económico y del costo-efectividad de la vacuna anti-rotavirus en Venezuela. Pan Am J Public Health 2006;20(4):213-222.

    Constenla D, Rivera M, Rheingans RD, Antil L, Vásquez ML. Evaluación económica de una eventual incorporación de la vacuna anti-rotavirus en el calendario de vacunación infantil en Honduras. Rev Med Hond 2006;74(1):19-29.

    Constenla D, Palacio R. Estimación del costo promedio de potenciales componentes de neumococcias en Uruguay. Eds.: M Hortal, Ines Iraola, Teresa Camou. In: Avances Multidisciplinarios para el Control Integral de S. pneumoniae – Uruguay – 10 años de experiencia, pp. 137-144, 2004.

    Hutton J, Constenla D, Hollenbach F. Deriving unit cost data for multinational economic evaluations. Value in Health 1999; 2(5).

    Constenla D, Munro V, Hutton J. The value of medicines: is there enough economic evidence? Value in Health 1998;1(1).

    Constenla D, Chambers M, Sigler, C. Patient-held instruments for recording ambulatory care resource use: experience in patients with diabetic foot ulcers. Value in Health 1998; 2(1).

    Johnston SR, Constenla DO, Moore J, Atkinson H, A´Hern RP, Dadian G, Riches PG, Gore ME. Randomised phase II trial of BCDT (Carmustine (BCNU), Cisplatin, Dacarbazine (DTIC) & Tamoxifen) with and without interferon alpha + Interleukin-2 (IL-2) in metastatic melanoma. British Journal of Cancer 1998; 77(8):1280-1286.

    Savage P, Constenla D, Fisher C, Shepherd JH, Barton DP, Blake P, Gore ME. Granulosa cell tumours of the ovary: demographics, survival and the management of advanced disease. Clinical Oncology 1998;10(4):242-5.

    Constenla DO, Hill ME, A'Hern RP, Henk JM, Rhys-Evans P, Breach N, Archer D, Gore ME. Chemotherapy for symptom control in squamous cell carcinomas of the head and neck. Annals of Oncology 1997; 8(5):445-449.

    Savage P, Constenla DO, Moore J, Gore ME. A phase II study of continuous infusional 5-Fluorouracil (5-FU) and subcutaneous Interleukin-2 (IL-2) in metastatic renal cancer. European Journal of Cancer 1997; 33 (7): 1149-1151

    Savage P, Constenla D, Fisher C, Thomas JM, Gore ME. The natural history and management of merkel cell carcinoma of the skin: a review of 22 patients treated at the Royal Marsden Hospital. Clinical Oncology 1997; 9(3):164-167.

    Hill ME, Constenla DO, A’Hern RP, Henk JM, Rhys-Evans P, Breach N, Archer D, Gore ME. Cisplatin (CP) and 5-fluoraucil for symptom control in advanced salivary adenoid cystic carcinoma. Oral Oncology 1997; 33(4): 275-278.